臂丛神经对高剂量再程放疗的耐受性
本研究分析了43例头颈部复发肿瘤再程放疗患者,通过形变配准融合初始与再程计划计算臂丛累积剂量,并用标准化神经病变工具筛查毒性。结论认为臂丛症状发生率低于预期,时间-剂量因素可预测并发症。
要点
- 臂丛症状发生率低于预期,与修复动力学和患者生存期较短有关。
核心结论
- 臂丛相关症状的发生率低于预期,归因于修复动力学和受试人群相对较短的生存期。
- 时间-剂量因素被证实可预测并发症。
研究设计与样本
- 回顾性分析43例头颈部复发肿瘤再程放疗患者,经初始与再程放疗计划审核确认臂丛存在重叠剂量。
- 采用标准化神经病变症状工具筛查臂丛损伤相关毒性。
- 通过形变图像配准将初始剂量分布融合至再程计划,计算臂丛累积剂量。
- 初始放疗至再程放疗的中位间隔为24个月(范围3-144个月)。
主要发现
- 有症状患者的主要主诉为同侧疼痛(54%)、麻木/刺痛(31%)和运动无力及/或手部精细操作困难(15%)。
- 臂丛累积Dmax范围为60.5 Gy至150.1 Gy(中位95.0 Gy)。
- 臂丛累积Dmean范围为20.2 Gy至111.5 Gy(中位63.8 Gy)。
临床怎么用
- 再程放疗评估臂丛耐受性时应融合初始与再程计划计算累积剂量,而非仅看单程剂量。
- 累积Dmax接近或超过95.0 Gy时需警惕臂丛神经病变风险,并结合再程间隔时间综合权衡。
局限性
- 样本量43例,作者指出受试人群生存期相对较短可能低估症状发生率。
- 原文未报告更长期的随访结果及多因素校正分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To study the tolerance of the brachial plexus to high doses of radiation exceeding historically accepted limits by analyzing human subjects treated with reirradiation for recurrent tumors of the head and neck. METHODS AND MATERIALS: Data from 43 patients who were confirmed to have received overlapping dose to the brachial plexus after review of radiation treatment plans from the initial and reirradiation courses were used to model the tolerance of this normal tissue structure. A standardized instrument for symptoms of neuropathy believed to be related to brachial plexus injury was utilized to screen for toxicity. Cumulative dose was calculated by fusing the initial dose distributions onto the reirradiation plan, thereby creating a composite plan via deformable image registration. The median elapsed time from the initial course of radiation therapy to reirradiation was 24 months (range, 3-144 months). RESULTS: The dominant complaints among patients with symptoms were ipsilateral pain (54%), numbness/tingling (31%), and motor weakness and/or difficulty with manual dexterity (15%). The cumulative maximum dose (Dmax) received by the brachial plexus ranged from 60.5 Gy to 150.1 Gy (median, 95.0 Gy). The cumulative mean (Dmean) dose ranged from 20.2 Gy to 111.5 Gy (median, 63.8 Gy). The 1-year freedom from brachial plexus-related neuropathy was 67% and 86% for subjects with a cumulative Dmax greater than and less than 95.0 Gy, respectively (P=.05). The 1-year complication-free rate was 66% and 87%, for those reirradiated within and after 2 years from the initial course, respectively (P=.06). CONCLUSION: The development of brachial plexus-related symptoms was less than expected owing to repair kinetics and to the relatively short survival of the subject population. Time-dose factors were demonstrated to be predictive of complications.
引用
- Chen AM, Yoshizaki T, Velez MA, et al. Tolerance of the Brachial Plexus to High-Dose Reirradiation. Int J Radiat Oncol Biol Phys. 2017. PMID: 28587056. doi:10.1016/j.ijrobp.2017.01.244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。